408 related articles for article (PubMed ID: 18676301)
1. Drug-induced torsades de pointes in patients aged 80 years or more.
Paran Y; Mashav N; Henis O; Swartzon M; Arbel Y; Justo D
Anadolu Kardiyol Derg; 2008 Aug; 8(4):260-5. PubMed ID: 18676301
[TBL] [Abstract][Full Text] [Related]
2. Takotsubo cardiomyopathy and QT interval prolongation: who are the patients at risk for torsades de pointes?
Samuelov-Kinori L; Kinori M; Kogan Y; Swartzon M; Shalev H; Guy D; Ferenidou F; Mashav N; Sadeh B; Atzmony L; Kliuk-Ben-Basat O; Steinvil A; Justo D
J Electrocardiol; 2009; 42(4):353-357.e1. PubMed ID: 19261294
[TBL] [Abstract][Full Text] [Related]
3. A case series of drug-induced long QT syndrome and Torsade de Pointes.
Tong KL; Lau YS; Teo WS
Singapore Med J; 2001 Dec; 42(12):566-70. PubMed ID: 11989578
[TBL] [Abstract][Full Text] [Related]
4. QT prolongation and Torsades de Pointes in patients previously treated with anthracyclines.
Arbel Y; Swartzon M; Justo D
Anticancer Drugs; 2007 Apr; 18(4):493-8. PubMed ID: 17351403
[TBL] [Abstract][Full Text] [Related]
5. Torsade de pointes induced by systemic antifungal agents: lessons from a retrospective analysis of published case reports.
Justo D; Zeltser D
Mycoses; 2006 Nov; 49(6):463-70. PubMed ID: 17022762
[TBL] [Abstract][Full Text] [Related]
6. Methadone-associated Torsades de Pointes (polymorphic ventricular tachycardia) in opioid-dependent patients.
Justo D; Gal-Oz A; Paran Y; Goldin Y; Zeltser D
Addiction; 2006 Sep; 101(9):1333-8. PubMed ID: 16911733
[TBL] [Abstract][Full Text] [Related]
7. Drug-induced torsades de pointes: a review of the Swedish pharmacovigilance database.
Aström-Lilja C; Odeberg JM; Ekman E; Hägg S
Pharmacoepidemiol Drug Saf; 2008 Jun; 17(6):587-92. PubMed ID: 18449951
[TBL] [Abstract][Full Text] [Related]
8. Ketoconazole induced torsades de pointes without concomitant use of QT interval-prolonging drug.
Mok NS; Lo YK; Tsui PT; Lam CW
J Cardiovasc Electrophysiol; 2005 Dec; 16(12):1375-7. PubMed ID: 16403073
[TBL] [Abstract][Full Text] [Related]
9. Proarrhythmic potential of antimicrobial agents.
Simkó J; Csilek A; Karászi J; Lorincz I
Infection; 2008 Jun; 36(3):194-206. PubMed ID: 18454341
[TBL] [Abstract][Full Text] [Related]
10. Frequency of high-risk use of QT-prolonging medications.
Allen LaPointe NM; Curtis LH; Chan KA; Kramer JM; Lafata JE; Gurwitz JH; Raebel MA; Platt R
Pharmacoepidemiol Drug Saf; 2006 Jun; 15(6):361-8. PubMed ID: 16178046
[TBL] [Abstract][Full Text] [Related]
11. Torsade de pointes induced by psychotropic drugs and the prevalence of its risk factors.
Justo D; Prokhorov V; Heller K; Zeltser D
Acta Psychiatr Scand; 2005 Mar; 111(3):171-6. PubMed ID: 15701100
[TBL] [Abstract][Full Text] [Related]
12. Reckless administration of QT interval-prolonging agents in elderly patients with drug-induced torsade de pointes.
Jackobson G; Carmel NN; Lotan D; Kremer A; Justo D
Z Gerontol Geriatr; 2018 Jan; 51(1):41-47. PubMed ID: 27878411
[TBL] [Abstract][Full Text] [Related]
13. QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system.
Pearson EC; Woosley RL
Pharmacoepidemiol Drug Saf; 2005 Nov; 14(11):747-53. PubMed ID: 15918160
[TBL] [Abstract][Full Text] [Related]
14. Sex differences in ventricular repolarization: from cardiac electrophysiology to Torsades de Pointes.
Abi-Gerges N; Philp K; Pollard C; Wakefield I; Hammond TG; Valentin JP
Fundam Clin Pharmacol; 2004 Apr; 18(2):139-51. PubMed ID: 15066127
[TBL] [Abstract][Full Text] [Related]
15. Magnitude of QT prolongation associated with a higher risk of Torsades de Pointes.
Lin YL; Kung MF
Pharmacoepidemiol Drug Saf; 2009 Mar; 18(3):235-9. PubMed ID: 19145580
[TBL] [Abstract][Full Text] [Related]
16. In vivo mechanisms precipitating torsades de pointes in a canine model of drug-induced long-QT1 syndrome.
Gallacher DJ; Van de Water A; van der Linde H; Hermans AN; Lu HR; Towart R; Volders PG
Cardiovasc Res; 2007 Nov; 76(2):247-56. PubMed ID: 17669388
[TBL] [Abstract][Full Text] [Related]
17. Beat-to-beat variability of QT intervals is increased in patients with drug-induced long-QT syndrome: a case control pilot study.
Hinterseer M; Thomsen MB; Beckmann BM; Pfeufer A; Schimpf R; Wichmann HE; Steinbeck G; Vos MA; Kaab S
Eur Heart J; 2008 Jan; 29(2):185-90. PubMed ID: 18156612
[TBL] [Abstract][Full Text] [Related]
18. Arrhythmias associated with fluoroquinolone therapy.
Falagas ME; Rafailidis PI; Rosmarakis ES
Int J Antimicrob Agents; 2007 Apr; 29(4):374-9. PubMed ID: 17241772
[TBL] [Abstract][Full Text] [Related]
19. Long QT syndrome caused by noncardiac drugs.
Viskin S; Justo D; Halkin A; Zeltser D
Prog Cardiovasc Dis; 2003; 45(5):415-27. PubMed ID: 12704598
[TBL] [Abstract][Full Text] [Related]
20. Giant T-U waves precede torsades de pointes in long QT syndrome: a systematic electrocardiographic analysis in patients with acquired and congenital QT prolongation.
Kirchhof P; Franz MR; Bardai A; Wilde AM
J Am Coll Cardiol; 2009 Jul; 54(2):143-9. PubMed ID: 19573731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
